Gastric cancer is a type of malignant cancer that forms the stomach’s inner lining. Risk factors such as age, diet, and stomach diseases can lead to the development of gastric cancer. Symptoms of gastric cancer include indigestion, heartburn, bloating, and stomach discomfort or pain. The presence of a huge patient population with gastrointestinal tumors, lymphoma, and adenocarcinoma, the increase in the geriatric population, and the rise in alcohol consumption and smoking are among the factors contributing to the growth of the gastric cancer diagnostic procedure market.
F. Hoffmann-La Roche AG. and Thermo Fisher Scientific Inc – Notable Market Players in Gastric Cancer Diagnostic Procedure Market
Key driving factors include the factors driving the gastric cancer diagnostic procedure market growth are rise in alcohol consumption and smoking. However, the shortage of medical laboratory professionals hinders the gastric cancer diagnostic procedure market growth.
The gastric cancer diagnostic procedure market is majorly comprised of top players involving Atlas-Link Biotech Co Ltd, Bio-Rad Laboratories Inc, MiRXES Pte Ltd, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, bioMerieux SA, Thermo Fisher Scientific Inc, Illumina Inc, Vela Diagnostics Holding Pte Ltd, and Myraid Genetics Inc. among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the gastric cancer diagnostic procedure market:
| Year | News |
| Aug -2022 | MiRXES launched a series of new capabilities—including an Industry 4.0 manufacturing facility, two new laboratories, and a collaborative multi-cancer screening research project. The new developments are aligned with MiRXES’ goal of advancing its research and production capabilities to develop miRNA-based disease detection tests. |
| Aug -2021 | GASTROClear is the world’s first RNA-powered blood test for the early detection of gastric cancer. The kit assesses the quantities of 12 microRNA biomarkers, allowing the company to detect as much as 87 percent of all gastric cancers. These include those at stage 0 of gastric cancer, also known as high-grade dysplasia |
| Aug-2022 | Roche announced the launch of the Digital LightCycler System, Roche’s first digital polymerase chain reaction ( PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods. |
| June-2022 | Roche announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey. |
| Aug-2021 | Myriad Genetics launched a new version of its MyRisk Hereditary Cancer Test. The test uses advanced technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites, including breast, colon, ovarian, endometrial, pancreatic, prostate, gastric cancers, and melanoma. |
| March-2022 | Myriad Genetics launched Precise Oncology Solutions, a new suite of tests combining germline testing, tumor profiling, and companion diagnostic options, including evaluation for Homologous Recombination Deficiency (HRD), an important cancer repair pathway. The suite includes Myriad’s new Precise Tumor Molecular Profile Test, developed in collaboration with Intermountain Precision Genomics, other leading healthcare providers, and industry partners. |
